ArticleAdvances in therapy2025
Real-World Perspectives on Switching Patients with Multiple Sclerosis from Anti-CD20 Therapy to Cladribine Tablets from USA-Based Advanced Practice Providers: A Podcast.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multiple sclerosis (MS) treatment landscape has expanded over time, becoming increasingly complex with the availability of more advanced high-efficacy therapies (HETs). In this evolving context, shared decision-making (SDM) between healthcare providers (HCPs) and patients is crucial for optimizing treatment and ensuring personalized care. Cladribine tablets (CladT), a highly effective therapy with a well-established safety profile, are approved in the USA for treating adults with relapsing MS, including those aged ≥ 50 years. Globally, more than 89,000 patients have received CladT. HCPs have considered transitioning patients from HETs, such as anti-CD20 monoclonal antibodies, to CladT. Further research is needed to understand factors influencing the decision to switch from an anti-CD20 therapy to CladT. This podcast explores real-world insights and challenges from USA-based advanced practice providers who have switched patients with MS from anti-CD20 therapies to CladT. The discussion builds on the results from a real-world retrospective survey of 100 HCPs aimed at understanding their rationale for transitioning patients from anti-CD20 therapies (e.g., ocrelizumab, ofatumumab, rituximab, ublituximab) to CladT. The survey also assessed differences in rationale for discontinuing anti-CD20 therapies and switching from anti-CD20 therapies to CladT between patients aged < 50 and ≥ 50 years. Findings revealed that the most common reasons for transitioning from anti-CD20 therapy to CladT included perception of increased efficacy on relapses (55%) and disability progression (54%), while common reasons for discontinuing anti-CD20 therapy included relapses (41%) and continued clinical activity (26%). In patients aged > 50 years, desire to avoid long-term immunosuppression (45%) was a key factor in choosing CladT after anti-CD20 therapy. Notably, AEs suggestive of immunosuppression or opportunistic infections were not reported in patients who transitioned to CladT, and no new safety signals, infections, or immunoglobulin reductions were observed. This podcast also highlights the economic benefits of CladT, the role of SDM, and recommendations based on clinical experiences. Podcast Transcript (MP4 217843 kb).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.